Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $88

Benzinga Newsdesk www.benzinga.com Positive 70.3%

Neg 0% Neu 0% Pos 70.3%

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raises the price target from $75 to $88.